Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma 22Leukemia, Myeloid, Acute 22Myelodysplastic Syndromes 21Breast Neoplasms 18Lymphoma, Non-Hodgkin 16Central Nervous System Neoplasms 14Burkitt Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia, Lymphocytic, Chronic, B-Cell 11Multiple Myeloma 10Leukemia, Myeloid, Accelerated Phase 10Hodgkin Disease 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Leukemia, Myeloid, Chronic-Phase 9Leukemia, Biphenotypic, Acute 9Brain Neoplasms 9Blast Crisis 9Neuroblastoma 8Medulloblastoma 8Lymphoma, Mantle-Cell 8Recurrence 7Lymphoma, B-Cell, Marginal Zone 7Hematologic Neoplasms 7Ovarian Neoplasms 6Congenital Abnormalities 6

Interventions

Transplantation Conditioning 1Thiotepa 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × High Risk Myeloid Malignancies × Thiotepa × Clear all
NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡